Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Supercomputer Simulates Beating Heart, Helping Drive Research

By BiotechDaily International staff writers
Posted on 04 Dec 2012
A new supercomputer had been built specifically to tackle weapon simulations, but before it goes into its intended work, it is generating cutting-edge cardiac simulations.

The Sequoia [IBM’s BlueGene/Q] holds the number two rank in the November 2012 TOP500 list of the world’s fastest computer systems [top ranked in the June 2012 TOP500 list].

Sequoia is bringing modeling and simulation and modeling to new peaks, timing in at 16.32 sustained petaflops (20 PF peak), enabling scientists to capture greater complexity in a shorter period. With this advanced capability, Lawrence Livermore US National Laboratory’s (LLNL; Livermore, CA, USA) scientists have been able to simulate the human heart down to the cellular level and use the resulting model to predict how the organ will respond to different drug compounds.

The simulations were made possible by an advanced modeling program, called Cardioid, which was designed by a group of scientists from LLNL and the IBM T. J. Watson Research Center (Yorktown Heights, NY, USA). The extremely scalable code simulates the electrophysiology of the heart. It functions by breaking down the heart into units: the smaller the unit, the more effective the model. Up to now, the optimal modeling programs could attain 0.2 mm in each direction. Cardioid can jump down to 0.1 mm. Where earlier, researchers could run the simulations for tens of heartbeats, Cardioid executing on Sequoia captures thousands of heartbeats.

Scientists are experiencing 300-fold speedups. It used to take 45 minutes to simulate just one beat, but now researchers can simulate an hour of heart activity--several thousand heartbeats--in seven hours. With the less sophisticated codes, it was impossible to model the heart’s response to a drug or perform an electrocardiogram trace for a particular heart disorder. That sort of testing entails longer run times, which was not possible before Cardioid.

The model could hypothetically evaluate a range of medications and devices such as pacemakers to examine their effect on the heart, creating an avenue for more effective and safer human testing. But it is particularly suited to examining arrhythmia, a disorder of the heart in which the organ does not pump blood efficiently. Arrhythmias can lead to congestive heart failure, an inability of the heart to supply sufficient blood flow to meet the needs of the body.

There are various types of medications that disrupt cardiac rhythms. Even those designed to prevent arrhythmias can be detrimental to some patients, and researchers do not yet completely understand precisely what causes these negative side effects. Cardioid will enable LLNL scientists to examine heart function as an antiarrhythmia drug enters the bloodstream. They will be able to identify when drug levels are highest and when they decline. “Observing the full range of effects produced by a particular drug takes many hours,” noted computational scientist Art Mirin of LLNL. “With Cardioid, heart simulations over this timeframe are now possible for the first time.”

The Livermore-IBM group is also working on a mechanical model that simulates the contraction of the heart and pumping of blood. The mechanical and electrical simulations will be allowed to interact with each other, adding more realism to the heart model.

The cardiac modeling research was performed during the system’s “shakedown period”--the set-up and assessment stage--and the scientists had to rush to complete in the allotted time span. Once Sequoia becomes classified, it is uncertain if it will still be available to run Cardioid and other unclassified programs, although access will certainly be more difficult since the computer’s key mission is running nuclear weapons codes.

Sequoia is an integral part of the US National Nuclear Security Administration’s (NNSA) Advanced Simulation and Computing (ASC) program, which is run by partner organizations LLNL, Los Alamos US National Laboratory, and Sandia National Laboratories. With 96 racks, 98,304 compute nodes, 1.6 million cores, and 1.6 petabytes of memory, Sequoia will help the NNSA fulfill its mission to “maintain and enhance the safety, security, reliability, and performance of the US nuclear weapons stockpile without nuclear testing.”

The Cardioid simulation has been chosen as a finalist in the 2012 Gordon Bell Prize competition, awarded each year to recognize supercomputing’s ultimate achievements. The scientists divulged their findings at the Supercomputing Conference in Salt Lake City (UT, USA), on November 13, 2012.

Related Links:

Lawrence Livermore U.S. National Laboratory
IBM T. J. Watson Research Center
US National Nuclear Security Administration




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).

Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.